# OnCo record paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022" ;
  schema:name "Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer"@en ;
  schema:description "In the first randomised US trial of neoadjuvant treatment for borderline resectable pancreatic cancer, eight cycles of modified FOLFIRINOX alone gave two-thirds of patients an 18-month survival, while replacing the last cycle with short-course radiotherapy did worse and that arm was stopped early."@en ;
  schema:url <https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2022.2319>, <https://pubmed.ncbi.nlm.nih.gov/35834226/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2022.2319> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Katz MHG, Shi Q, Meyers J, et al." ;
  onco:cancers <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .